Bull, base and bear scenarios, opening on what this business has actually done — its realised growth rates and its own P/E range, not round numbers we chose.
Projections are part of Pro
Set the growth, margin and multiple yourself and watch the price land where your assumptions put it — for Karyopharm Therapeutics Inc. and every other company we cover.
Try it first on NVDA, AAPL, META, NKE or CAKE, where it is open to everyone.
$0.02-56.5%Nov 10 close
Figures through June 30, 2026, from the 10-Q filed August 13, 2026
Company outlook: revenue of $130M to $150M for Fiscal year 2026 — down 4.2% on a year earlier ($146.1M)